SCHEMBL20511633

SCHEMBL20511633

CC(N)c1cccc2ccoc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
NFKB1 P19838 1/20 0.41
PNMT P11086 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
GLA P06280 1/20 0.40
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
CASP3 P42574 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3795346 0.84 GABRA1 (0.41) CYP1A2CYP3A4CYP2D6LMNAMEN1
SCHEMBL16844552 0.81 CYP1A2 (0.36) CYP1A2CYP3A4CYP2D6LMNAMEN1
SCHEMBL16855175 0.81 CYP1A2 (0.36) CYP1A2CYP3A4CYP2D6LMNAMEN1
SCHEMBL30701213 0.81 CYP1A2 (0.36) CYP1A2CYP3A4CYP2D6LMNAMEN1
SCHEMBL26462986 0.81 MEN1 (0.36) CYP1A2CYP3A4CYP2D6MEN1NPC1
SCHEMBL24312374 0.81 MEN1 (0.36) CYP1A2CYP3A4CYP2D6MEN1NPC1
SCHEMBL3797966 0.78 TSHR (0.44) CYP1A2CYP3A4CYP2D6MEN1NPC1
SCHEMBL26864180 0.78 TSHR (0.44) CYP1A2CYP3A4CYP2D6MEN1NPC1
SCHEMBL30684489 0.74 HTR2A (0.44) SLC6A2SLC6A4SLC6A3
SCHEMBL5988407 0.74 HTR2A (0.44) SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083857-A1 2-Methyl-Quinazolines Bayer Pharma AG (DE) 2024-03-14 US disclosed
US-20220235013-A1 2-METHYL-QUINAZOLINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-07-28 US disclosed
EP-3601267-A1 2-METHYL-QUINAZOLINES Bayer Pharma Aktiengesellschaft (DE) 2020-02-05 EP disclosed
WO-2018172250-A1 2-METHYL-QUINAZOLINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083857-A1 2-Methyl-Quinazolines NRAS, KRAS, KSR2 CYP1A2 404/4885CYP3A4 1232/4885CYP2D6 469/4885
US-20220235013-A1 2-METHYL-QUINAZOLINES NRAS, KRAS, KSR2 CYP1A2 404/4885CYP3A4 1232/4885CYP2D6 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.